

CURRICULUM VITAE

FORMATO
EUROPEO PER IL
CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome e Cognome

Valeria Merz

Incarico attuale

Dirigente medico

ISTRUZIONE
E FORMAZIONE

• Date (da – a)

Ottobre 2019 – in corso
Dottorato di ricerca in “Infiammazione, immunità e cancro” presso l’Università degli Studi di Verona

Dicembre 2014 – Dicembre 2019
Medico in formazione specialistica in Oncologia medica presso l’Università degli Studi di Verona
Particolare interesse in ambito gastroenterico.
Voto finale: 60/60 con Lode

Ottobre 2007 - Marzo 2014
Laurea in Medicina e Chirurgia
Università degli Studi di Verona, Facoltà di Medicina e Chirurgia

Tesi di laurea: “L’inibizione del fibroblast growth factor receptor 3 come strategia terapeutica per la modulazione della resistenza al trastuzumab nel cancro gastrico”
Relatore: Prof. Giampaolo Tortora
Voto finale: 110/110 con Lode

• Nome e tipo di istituto
di istruzione o formazione

• Qualifica conseguita

ESPERIENZA LAVORATIVA

• Date (da – a)

Gennaio 2020 – in corso
Dirigente medico in Oncologia medica presso l’Ospedale Santa Chiara di Trento

• Nome e indirizzo del datore di
lavoro

- Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

.

MADRELINGUA

Italiana

ALTRE LINGUE

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

[buono]

[buono]

[buono]

CAPACITÀ E COMPETENZE

TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

PUBBLICAZIONI

1. Piro G, Giacomuzzi S, Bencivenga M, Carbone C, Verlato G, Frizziero M, Zanutto M, Mina MM, Merz V, Santoro R, Zanoni A, De Manzoni G, Tortora G, Melisi D. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. *Br J Cancer*. 2015 Sep 15
2. Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacomuzzi S, Aprile G, Simionato F, Boschi F, Zanutto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, Melisi D. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. *Clin Cancer Res*. 2016 Jun 7
3. Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, Casolino R, Santoro R, Mina MM, Zecchetto C, Merz V, Scarpa A, Bassi C, Tortora G, Melisi D. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. *Oncoimmunology*. 2017 Apr 28
4. Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Ali G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanutto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. *Clin Cancer Res*. 2017 Aug 1
5. Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, De Franceschi L, Scarpa A, Tortora G, Melisi D. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. *Int J Obes*. 2017 Nov 20
6. Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G, Melisi D. Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. *Int J Mol Sci*. 2018 Feb 1 ^[1] _[SEP]
7. Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprari D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. *JAMA Surg* 2019 Jul 24
8. Gueorguieva I, Tabernero J, Melisi D, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor- β inhibitor galunisertib in patients with pancreatic cancer. *Cancer Chemother Pharmacol*. 2019 Sep 3
9. Messina C, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, Salati M, Messina M, Carnaghi C, Caffo O. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials. *Crit Rev Oncol Hematol*. 2019 Sep 9
10. Salati M, Baldessari C, Bonetti LR, Messina C, Merz V, Cerbelli B, Botticelli A. NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. *Crit Rev Oncol Hematol*. 2019 Dec
11. Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, Melisi D. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. *J Gastric Cancer*. 2019 Dec
12. Santoro R, Zanutto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, Melisi D. Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer. *Mol Cancer Ther*. 2020 Jan
13. Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, Milella M, Caffo O, Melisi D. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. *Cancers (Basel)*. 2020 Apr 30
14. Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, Melisi D. Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer. *Clin Cancer Res*. 2020 Sep
15. Merz V*, Zecchetto C*, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacomuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, Melisi D. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. *Ther Adv Med Oncol*. 2020; Jul 7

16. Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. *Future Oncol*. 2020 Oct 9. doi: 10.2217/fo-2020-0726. Online ahead of print
17. Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietrolungo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. *J Immunother Cancer*. 2020 Oct;8(2):e001154
18. Simionato F*, Zecchetto C*, Merz V*, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuveri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbriellini A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, Melisi D. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nTRO trial. *Ther Adv Med Oncol*. 2020 Sep 4;12:1758835920947969
19. Messina C, Salati M, Messina M, Cattrini C, Merz V, Caffo O. Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: a pooled analysis of randomized trials. *Eur J Clin Invest*. 2020 Dec 31;e13483. Online ahead of print.
20. Merz V, Ferro A, Piras EM, Zanutto A, Caffo O, Messina C. Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience. *JCO Oncol Pract*. 2021 Jan;17(1):e44-e52
21. Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. *J Immunother Cancer*. 2021 Mar;9(3):e002068
22. Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, Melisi D. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. *Front Oncol*. 2021 Mar 11;11:638360
23. Melisi D, Cavaliere A, Gobbo S, Fasoli G, Allegrini V, Simionato F, Gaule M, Casalino S, Pesoni C, Zecchetto C, Merz V, Mambrini A, Barbi E, Girelli R, Giardino A, Frigerio I, Scalamogna R, Avitabile A, Castellani S, Milella M, Butturini G. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. *Pancreatol*. 2021 Apr 19;S1424-3903(21)00143-5
24. Vernuccio F, Messina C, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. *Diagnostics (Basel)*. 2021 Nov 22;11(11):2166
25. Salati M, Rizzo A, Merz V, Messina C, Francesco C, Gelsomino F, Spallanzani A, Ricci AD, Palloni A, Frega G, De Lorenzo S, Carotenuto P, Pettorelli E, Benatti S, Luppi G, Melisi D, Brandi G, Dominici M. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. *Expert Rev Gastroenterol Hepatol*. 2022 Jan;16(1):73-79. doi: 10.1080/17474124.2022.2017772
26. Gaule M, Pesoni C, Quinzii A, Zecchetto C, Casalino S, Merz V, Contarelli S, Pietrobono S, Vissio E, Molinaro L, Manzin E, Volpato R, Vellani G, Melisi D. Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion. *JCO Precis Oncol*. 2022 Jan;6:e2100400

27. Salati M, Marcheselli L, Messina C, Merz V, Messina M, Carotenuto P, Caputo F, Gelsomino F, Spallanzani A, Reggiani Bonetti L, Caramaschi S, Luppi G, Dominici M, Ghidini M. Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy. *Cancer Manag Res*. 2022 Mar 5;14:983-993
28. Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. *Front Surg*. 2022 May 4;9:866173.
29. Caputo F, c Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study. *Clin Res Hepatol Gastroenterol*. 2022 Oct;46(8):101955.
30. Quinzii A, Zecchetto C, Casalino S, Gaule M, Pesoni C, Merz V, Contarelli S, Pietrobono S, Benhadji KA, Melisi D. Clinical Response to Fufitinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports. *Clin Drug Investig*. 2022 Aug;42(8):697-701.
31. Rizzo A, Salati M, Frega G, Merz V, Caputo F, Di Federico A, Palloni A, Carloni R, Ricci AD, Gadaleta-Caldarola G, Messina C, Spallanzani A, Gelsomino F, Benatti S, Luppi G, Melisi D, Dominici M, Brandi G. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. *Medicina (Kaunas)*. 2022 Oct 27;58(11):1543.
32. van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquez MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cernul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. *Nat Med*. 2023 Mar;29(3):605-614.
33. Zecchetto C, Quinzii A, Casalino S, Gaule M, Pesoni C, Merz V, Pietrobono S, Mangiameli D, Pasquato M, Milleri S, Giacomuzzi S, Bencivenga M, Tomezzoli A, de Manzoni G, Melisi D. Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. *J Pers Med*. 2023 Mar 11;13(3):508
34. Procaccio L*, Merz V*, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, Pinto C, Zecchetto C, Barsotti G, De Vita F, Milella M, Antonuzzo L, Scartozzi M, Zaniboni A, Spadi R, Casalino S, Bergamo F, De Toni C, Melisi D, Lonardi S. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. *Cancer Med*. 2023 Jul;12(13):14337-14345.
35. Pietrobono S, Sabbadini F, Bertolini M, Mangiameli D, De Vita V, Fazzini F, Lunardi G, Casalino S, Scarlato E, Merz V, Zecchetto C, Quinzii A, Di Conza G, Lahn M, Melisi D. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. *Cancer Res*. 2024 Jan 2;84(1):118-132
36. Bencivenga M, Torroni L, Dal Cero M, Quinzii A, Zecchetto C, Merz V, Casalino S, Taus F, Pietrobono S, Mangiameli D, Filippini F, Alloggio M, Castelli C, Iglesias M, Pera M, Melisi D. YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer. *J Pers Med*. 2023 Aug 24;13(9):1294
37. Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbriellini A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nTRO trial. *Eur J Cancer*. 2024 Jan;196:113430.
38. Merz V, Messina C, Zecchetto C, Quinzii A, Frisinghelli M, Trentin C, Salati M, Caffo O, Melisi D. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials. *Clin Oncol (R Coll Radiol)*. 2024 Feb;36(2):87-97. doi: 10.1016/j.clon.2023.12.005. Epub 2023 Dec 15.
39. Melisi D, Casalino S, Pietrobono S, Quinzii A, Zecchetto C, Merz V. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. *Ther Adv Med Oncol*. 2024 Apr 4;16:17588359241234487.

40. Merz V, Maines F, Marcucci S, Sartori C, Frisinghelli M, Trentin C, Kadrija D, Carbone FG, Michielan A, Gabbrielli A, Melisi D, Barbareschi M, Brolese A, Caffo O. Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma. J Cancer Res Clin Oncol. 2024 Jul 11;150(7):347
41. Casalino S, Zecchetto C, Merz V, Quinzii A, Pietrobono S, Melisi D. Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma. Ann Oncol. 2024 Sep;35(9):760-761.
42. Pietrobono S, Bertolini M, De Vita V, Sabbadini F, Fazzini F, Frusteri C, Scarlato E, Mangiameli D, Quinzii A, Casalino S, Zecchetto C, Merz V, Melisi D. CCL3 predicts exceptional response to TGF β inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. NPJ Precis Oncol. 2024 Oct 30;8(1):246.